An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability

BACKGROUND: Ocrelizumab, an anti-CD20 humanized monoclonal antibody, reduced disease progression in pivotal trials of patients with relapsing (OPERA I, OPERA II) and primary progressive (ORATORIO) multiple sclerosis (MS). These effects may be particularly important among patients with increased disa...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolinsky, Jerry S, Engmann, Natalie J, Pei, Jinglan, Pradhan, Ashish, Markowitz, Clyde, Fox, Edward J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079307/
https://www.ncbi.nlm.nih.gov/pubmed/32206332
http://dx.doi.org/10.1177/2055217320911939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079307/
https://www.ncbi.nlm.nih.gov/pubmed/32206332
http://dx.doi.org/10.1177/2055217320911939

Ejemplares similares